Mahesh Patel Biography and Net Worth

CEO of Lipocine

Dr. Mahesh V. Patel has more than 20 years of technology and product development experience in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, Dr. Patel led drug delivery research and development at Pharmacia and Upjohn in Kalamazoo, MI. He received his MS in Physical Pharmacy at the University of Cincinnati and his PhD in Pharmaceutics from the University of Utah. His areas of expertise include strategic planning, technology assessment/development, technical management and product research and development.

What is Mahesh V. Patel's net worth?: The estimated net worth of Mahesh V. Patel is at least $653,101.44 as of May 25th, 2023. Dr. Patel owns 107,418 shares of Lipocine stock worth more than $653,101 as of November 2nd. This net worth evaluation does not reflect any other assets that Dr. Patel may own. Additionally, Dr. Patel receives a salary of $762,530.00 as CEO at Lipocine. Learn More about Mahesh V. Patel's net worth.
How old is Mahesh V. Patel?: Dr. Patel is currently 67 years old. There are 3 older executives and no younger executives at Lipocine. Learn More on Mahesh V. Patel's age.
What is Mahesh V. Patel's salary?: As the CEO of Lipocine Inc., Dr. Patel earns $762,530.00 per year. Learn More on Mahesh V. Patel's salary.
How do I contact Mahesh V. Patel?: The corporate mailing address for Dr. Patel and other Lipocine executives is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. Lipocine can also be reached via phone at (801) 994-7383 and via email at [email protected]. Learn More on Mahesh V. Patel's contact information.
Has Mahesh V. Patel been buying or selling shares of Lipocine?: Mahesh V. Patel has not been actively trading shares of Lipocine during the last ninety days. Most recently, on Thursday, May 25th, Mahesh V. Patel bought 8,706 shares of Lipocine stock. The stock was acquired at an average cost of $5.03 per share, with a total value of $43,791.18. Following the completion of the transaction, the chief executive officer now directly owns 107,418 shares of the company's stock, valued at $540,312.54. Learn More on Mahesh V. Patel's trading history.

Mahesh V. Patel Insider Trading History at Lipocine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/25/2023	Buy	8,706	$5.03	$43,791.18	107,418
3/24/2023	Buy	8,823	$5.44	$47,997.12	98,711
3/17/2023	Buy	2,941	$5.61	$16,499.01	89,887
9/27/2022	Buy	5,882	$6.97	$40,997.54	82,534
5/16/2022	Buy	2,941	$13.09	$38,497.69	76,652
11/18/2021	Buy	1,470	$18.53	$27,239.10
12/16/2020	Sell	882	$22.95	$20,241.90
12/4/2020	Sell	2,558	$26.69	$68,273.02	65,800
12/31/2019	Buy	2,352	$7.14	$16,793.28
12/10/2019	Buy	1,470	$6.80	$9,996.00	54,918
12/4/2019	Sell	2,558	$6.63	$16,959.54
11/26/2019	Buy	1,470	$7.31	$10,745.70	46,081
11/18/2019	Buy	2,941	$6.80	$19,998.80	43,355
12/29/2017	Sell	352	$59.16	$20,824.32
12/29/2017	Sell	352	$59.16	$20,824.32	42,830
9/30/2015	Buy	235	$201.28	$47,300.80	52,213
11/25/2014	Buy	117	$86.70	$10,143.90
11/24/2014	Buy	117	$92.65	$10,840.05
11/14/2014	Buy	117	$86.02	$10,064.34
11/13/2014	Buy	117	$85.85	$10,044.45

Mahesh V. Patel Buying and Selling Activity at Lipocine

Lipocine Company Overview

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $6.08

$5.54

$6.13

50 Day Range

MA: $4.67

$3.52

$6.08

2 Week Range

Now: $6.08

$2.35

$11.79

Volume

71,205 shs

Average Volume

47,320 shs

Market Capitalization

$32.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Election warning coming true…

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.